Back Back
Cell No. : Cell Name
RCB4455 : PC-9  update : 2024/02/16
CommentHuman cell line derived from lung adenocarcinoma cells. Differentiated type. Previous name:PC-14(RCB0446)
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Originator Tsuji, K. & Hayata, Y.
Year of deposit 1989
Another name RCB0446 PC-14
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Tissue lung
Classification cancer
Lifespan infinite
Morphology other
Cellosaurus(Expasy) CVCL_B260
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium RPMI1640 + 10% FBS
Antibiotics Free
Passage method pipetting or 0.25% Trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 1-2 times/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
STR(human) OK
deposit info
lot info
D5S818 D13S317 D7S820 D16S539 vWA TH01 Amelogenin TPOX CSF1PO
11 8 10,11 9 17 7 X 11 11
deposit info
lot info
Reference information Reference 0
User's Publication 116

To topTop

To topTop
User's Publication
17817  Ohkawa Y, Kitano M, Maeda K, Nakano M, Kanto N, Kizuka Y, Seike M, Azuma A, Yamaguchi Y, Ookawara T, Miyoshi E, Taniguchi N.  Core Fucosylation Is Required for the Secretion of and the Enzymatic Activity of SOD3 in Nonsmall-Cell Lung Cancer Cells  Antioxid Redox Signal  2023  Mar 6  PubMed ID: 36606688   DOI: 10.1089/ars.2022.0010
19976  Gunasekaran P, Hwang YS, Lee GH, Park J, Kim JG, La YK, Park NY, Kothandaraman R, Yim MS, Choi J, Kim HN, Park IY, Lee SJ, Kim MH, Cha-Molstad H, Shin SY, Ryu EK, Bang JK.  Degradation of Polo-like Kinase 1 by the Novel Poly-Arginine N-Degron Pathway PROTAC Regulates Tumor Growth in Nonsmall Cell Lung Cancer  J Med Chem  2023  Dec 17  PubMed ID: 38105611   DOI: 10.1021/acs.jmedchem.3c01493
20946  Takumi Y, Arai S, Suzuki C, Fukuda K, Nishiyama A, Takeuchi S, Sato H, Matsumoto K, Sugio K, Yano S.  MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements.  Cancer Med  2023  12(5):5809-5820  PubMed ID: 36416133   DOI: 10.1002/cam4.5342
21119  Tokumo K, Masuda T, Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Okada M, Hamada H, Hattori N.  Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal Transition.  Cancers (Basel)  2023  15(4)  PubMed ID: 36831438   DOI: 10.3390/cancers15041092
21131  Konishi H, Haga Y, Lin Y, Tsujino H, Higashisaka K, Tsutsumi Y.  Osimertinib-tolerant lung cancer cells are susceptible to ferroptosis.  Biochem Biophys Res Commun  2023  641:116-122  PubMed ID: 36527745   DOI: 10.1016/j.bbrc.2022.12.029
21136  Sumimoto H, Takano A, Igarashi T, Hanaoka J, Teramoto K, Daigo Y.  Oncogenic epidermal growth factor receptor signal-induced histone deacetylation suppresses chemokine gene expression in human lung adenocarcinoma.  Sci Rep  2023  13(1):5087  PubMed ID: 36991099   DOI: 10.1038/s41598-023-32177-4
21224  Kim M, Kim S, Yim J, Keam B, Kim TM, Jeon YK, Kim DW, Heo DS.  Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.  Cancer Res Treat  2023    PubMed ID: 37218137   DOI: 10.4143/crt.2023.311
17574  Suzuki C, Nishiyama A, Arai S, Tange S, Tajima A, Tanimoto A, Fukuda K, Takumi Y, Kotani H, Takeuchi S, Yanagimura N, Ohtsubo K, Yamamoto N, Omori K, Yano S.  Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells  Cancer Sci  2022  113(7):2323-2335  PubMed ID: 35363931   DOI: 10.1111/cas.15354
20516  Fan D, Yang Y, Zhang W.  A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells.  BMC Pulm Med  2022  22(1):27  PubMed ID: 34996416   DOI: 10.1186/s12890-021-01731-z
20523  Gebreyesus ST, Siyal AA, Kitata RB, Chen ES, Enkhbayar B, Angata T, Lin KI, Chen YJ, Tu HL.  Streamlined single-cell proteomics by an integrated microfluidic chip and data-independent acquisition mass spectrometry.  Nat Commun  2022  13(1):37  PubMed ID: 35013269   DOI: 10.1038/s41467-021-27778-4
20529  Katayama Y, Yamada T, Tokuda S, Okura N, Nishioka N, Morimoto K, Tanimura K, Morimoto Y, Iwasaku M, Horinaka M, Sakai T, Kita K, Yano S, Takayama K.  Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells.  Cancer Med  2022  11(4):944-955  PubMed ID: 35029047   DOI: 10.1002/cam4.4504
20595  Matsushige T, Sakabe T, Umekita Y.  Investigation of the Subcellular Localization-Dependent Anti- or Pro-Tumor Functions of Maspin in Human Lung Adenocarcinoma Cell Line.  Yonago Acta Med  2022  65(1):44-52  PubMed ID: 35221759   DOI: 10.33160/yam.2022.02.006
16503  Tsuchiya K, Yoshimura K, Iwashita Y, Inoue Y, Ohta T, Watanabe H, Yamada H, Kawase A, Tanahashi M, Ogawa H, Funai K, Shinmura K, Suda T, Sugimura H.  m 6 A demethylase ALKBH5 promotes tumor cell proliferation by destabilizing IGF2BPs target genes and worsens the prognosis of patients with non-small-cell lung cancer  Cancer Gene Ther  2022  Mar 22  PubMed ID: 35318440   DOI: 10.1038/s41417-022-00451-8
16726  Grinkevitch V, Wappett M, Crawford N, Price S, Lees A, McCann C, McAllister K, Prehn J, Young J, Bateson J, Gallagher L, Michaut M, Iyer V, Chatzipli A, Barthorpe S, Ciznadija D, Sloma I, Wesa A, Tice DA, Wessels L, Garnett M, Longley DB, McDermott U, McDade SS.  Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists  Mol Cancer Ther  2022  21(4):594-606  PubMed ID: 35086954   DOI: 10.1158/1535-7163.MCT-21-0532
16854  Masaki Takahashi, Yoshifumi Hashimoto, Yoshikazu Nakamura  Anti-TGF-β1 aptamer enhances therapeutic effect of tyrosine kinase inhibitor, gefitinib, on non-small cell lung cancer in xenograft model  Molecular Therapy - Nucleic Acids  2022  29:969-978  PubMed ID: 36189081   DOI: 10.1016/j.omtn.2022.06.001
20821  Li C, Zheng H, Xiong J, Huang Y, Li H, Jin H, Ai S, Wang Y, Su T, Sun G, Xiao X, Fu T, Wang Y, Gao X, Liang P.  miR-596-3p suppresses brain metastasis of non-small cell lung cancer by modulating YAP1 and IL-8.  Cell Death Dis  2022  13(8):699  PubMed ID: 35961957   DOI: 10.1038/s41419-022-05062-7
20848  Satoh K, Sakai S, Nishizuka M.  Knockdown of RhoQ, a member of Rho GTPase, accelerates TGF-β-induced EMT in human lung adenocarcinoma.  Biochem Biophys Rep  2022  32:101346  PubMed ID: 36120491   DOI: 10.1016/j.bbrep.2022.101346
20859  Onishi T, Takashima T, Kurashige M, Ohshima K, Morii E.  Mutually exclusive expression of EZH2 and H3K27me3 in non-small cell lung carcinoma.  Pathol Res Pract  2022  238:154071  PubMed ID: 35985089   DOI: 10.1016/j.prp.2022.154071
20935  Deng H, Lei Q, Wang C, Wang Z, Chen H, Wang G, Yang N, Huang D, Yu Q, Yao M, Xiao X, Zhu G, Cheng C, Li Y, Li F, Tian P, Li W.  A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations.  Nat Commun  2022  13(1):6944  PubMed ID: 36376325   DOI: 10.1038/s41467-022-34627-5
20104  Abe K, Kanehira M, Ohkouchi S, Kumata S, Suzuki Y, Oishi H, Noda M, Sakurada A, Miyauchi E, Fujiwara T, Harigae H, Okada Y.  Targeting stanniocalcin-1-expressing tumor cells elicits efficient antitumor effects in a mouse model of human lung cancer.  Cancer Med  2021    PubMed ID: 33826244   DOI: 10.1002/cam4.3852
14291  Isomura H, Taguchi A, Kajino T, Asai N, Nakatochi M, Kato S, Suzuki K, Yanagisawa K, Suzuki M, Fujishita T, Yamaguchi T, Takahashi M, Takahashi T.  Conditional Ror1 knockout reveals crucial involvement in lung adenocarcinoma development and identifies novel HIF-1α regulator  Cancer Sci  2021  112(4):1614-1623  PubMed ID: 33506575   DOI: 10.1111/cas.14825
14368  Khaledian B, Taguchi A, Shin-Ya K, Kondo-Ida L, Kagaya N, Suzuki M, Kajino T, Yamaguchi T, Shimada Y, Takahashi T.  Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma  Cancer Sci  2021  112(3):1225-1234  PubMed ID: 33370472   DOI: 10.1111/cas.14786
20304  Nakasone S, Suzuki A, Okazaki H, Onodera K, Zenkoh J, Ishii G, Suzuki Y, Tsuboi M, Tsuchihara K.  Predictive markers based on transcriptome modules for vinorelbine-based adjuvant chemotherapy for lung adenocarcinoma patients.  Lung Cancer  2021  158:115-125  PubMed ID: 34157583   DOI: 10.1016/j.lungcan.2021.06.011
20365  He W, Qin M, Cai Y, Gao X, Cao S, Wang Z, Chen H, Xu R.  Downregulation of HOXC6 by miR-27a ameliorates gefitinib resistance in non-small cell lung cancer.  Am J Cancer Res  2021  11(9):4329-4346  PubMed ID: 34659890  
15836  Nanamiya R, Saito-Koyama R, Miki Y, Inoue C, Asavasupreechar T, Abe J, Sato I, Sasano H.  EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer  Int J Mol Sci  2021  22(16):8522  PubMed ID: 34445227   DOI: 10.3390/ijms22168522
15839  Poels KE, Schoenfeld AJ, Makhnin A, Tobi Y, Wang Y, Frisco-Cabanos H, Chakrabarti S, Shi M, Napoli C, McDonald TO, Tan W, Hata A, Weinrich SL, Yu HA, Michor F.  dentification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer  Nat Commun  2021  12(1):3697  PubMed ID: 34140482   DOI: 10.1038/s41467-021-23912-4
15840  Fukuda K, Otani S, Takeuchi S, Arai S, Nanjo S, Tanimoto A, Nishiyama A, Naoki K, Yano S.  Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer  Cancer Sci  2021  112(9):3784-3795  PubMed ID: 34145930   DOI: 10.1111/cas.15035
15846  Kawana S, Saito R, Miki Y, Kimura Y, Abe J, Sato I, Endo M, Sugawara S, Sasano H.  Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma  Cancer Med  2021  10(2):718-727  PubMed ID: 33305905   DOI: 10.1002/cam4.3639
15883  Xue L, Gao X, Zhang H, Tang J, Wang Q, Li F, Li X, Yu X, Lu Z, Huang Y, Tang R, Yang W.  Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment  BMC Cancer  2021  21(1):1134  PubMed ID: 34686154   DOI: 10.1186/s12885-021-08859-5
16219  Jeongmin Hong, Aya Shiba‐Ishii, Yunjung Kim, Masayuki Noguchi, Noriaki Sakamoto  Ovarian carcinoma immunoreactive antigen domain 2 controls mitochondrial apoptosis in lung adenocarcinoma  Cancer Sci  2021  112(12):5114-5126  PubMed ID: 34628698   DOI: 10.1111/cas.15160
16281  Nachankar A, Oike T, Hanaoka H, Kanai A, Sato H, Yoshida Y, Obinata H, Sakai M, Osu N, Hirota Y, Takahashi A, Shibata A, Ohno T.  64 Cu-ATSM Predicts Efficacy of Carbon Ion Radiotherapy Associated with Cellular Antioxidant Capacity  Cancers (Basel)  2021  13(24):6159  PubMed ID: 34944777   DOI: 10.3390/cancers13246159
20624  Nozaki M, Nishizuka M.  Repression of RhoJ expression promotes TGF-β-mediated EMT in human non-small-cell lung cancer A549cells.  Biochem Biophys Res Commun  2021  566:94-100  PubMed ID: 34119829   DOI: 10.1016/j.bbrc.2021.06.004
16516  Tsuchiya K, Yoshimura K, Inoue Y, Iwashita Y, Yamada H, Kawase A, Watanabe T, Tanahashi M, Ogawa H, Funai K, Shinmura K, Suda T, Sugimura H.  YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer  Oncoimmunology  2021  10(1):1962656  PubMed ID: 34408926   DOI: 10.1080/2162402X.2021.1962656
18105  Liu J, Han X, Chen L, Han D, Mu X, Hu X, Wu H, Wu H, Liu W, Zhao Y.  TRIM28 is a distinct prognostic biomarker that worsens the tumor immune microenvironment in lung adenocarcinoma  Aging (Albany NY)  2020  12(20):20308-20331  PubMed ID: 33091876   DOI: 10.18632/aging.103804
7054  Arai S, Takeuchi S, Fukuda K, Taniguchi H, Nishiyama A, Tanimoto A, Satouchi M, Yamashita K, Ohtsubo K, Nanjo S, Kumagai T, Katayama R, Nishio M, Zheng MM, Wu YL, Nishihara H, Yamamoto T, Nakada M, Yano S.  Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer.  J Thorac Oncol  2020  15(5):752-765  PubMed ID: 31972351   DOI: 10.1016/j.jtho.2020.01.001
11955  Ren T, Fan XX, Wang MF, Duan FG, Wei CL, Li RZ, Jiang ZB, Wang YW, Yao XJ, Chen MW, Tang YJ, Leung EL.  miR‑20b promotes growth of non‑small cell lung cancer through a positive feedback loop of the Wnt/β‑catenin signaling pathway.  Int. J. Oncol.  2020    PubMed ID: 31894264   DOI: 10.3892/ijo.2019.4940
12050  Azuma Y, Yokobori T, Mogi A, Yajima T, Kosaka T, Iijima M, Shimizu K, Shirabe K, Kuwano H.  Cancer exosomal microRNAs from gefitinib-resistant lung cancer cells cause therapeutic resistance in gefitinib-sensitive cells.  Surg. Today  2020    PubMed ID: 32052182   DOI: 10.1007/s00595-020-01976-x
12085  Lin Y, Higashisaka K, Shintani T, Maki A, Hanamuro S, Haga Y, Maeda S, Tsujino H, Nagano K, Fujio Y, Tsutsumi Y.  Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/β-catenin and NF-κB pathways, in lung adenocarcinoma cells.  Sci Rep  2020    PubMed ID: 32179851   DOI: 10.1038/s41598-020-61727-3
12089  Tanaka H, Hino H, Moriya S, Kazama H, Miyazaki M, Takano N, Hiramoto M, Tsukahara K, Miyazawa K.  Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin.  Biochem Biophys Rep  2020    PubMed ID: 32195376   DOI: 10.1016/j.bbrep.2020.100750
13153  Suzuki S, Yamamoto M, Sanomachi T, Togashi K, Sugai A, Seino S, Okada M, Yoshioka T, Kitanaka C.  Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing.  Biomedicines  2020    PubMed ID: 32764319   DOI: 10.3390/biomedicines8080273
13224  Wang R, Yamada T, Kita K, Taniguchi H, Arai S, Fukuda K, Terashima M, Ishimura A, Nishiyama A, Tanimoto A, Takeuchi S, Ohtsubo K, Yamashita K, Yamano T, Yoshimura A, Takayama K, Kaira K, Taniguchi Y, Atagi S, Uehara H, Hanayama R, Matsumoto I, Han X, Matsumoto K, Wang W, Suzuki T, Yano S.  Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.  Nat Commun  2020    PubMed ID: 32929081   DOI: 10.1038/s41467-020-18442-4
13283  Arai S, Takeuchi S, Fukuda K, Tanimoto A, Nishiyama A, Konishi H, Takagi A, Takahashi H, Ong ST, Yano S.  Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism.  J Med Invest  2020    PubMed ID: 33148913   DOI: 10.2152/jmi.67.343
13543  Okuno D, Sugiura Y, Sakamoto N, Tagod MSO, Iwasaki M, Noda S, Tamura A, Senju H, Umeyama Y, Yamaguchi H, Suematsu M, Morita CT, Tanaka Y, Mukae H.  Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells  Front Immunol  2020  11:1405  PubMed ID: 32793196   DOI: 10.3389/fimmu.2020.01405
13922  Kim H, Ishibashi K, Iijima M, Kuroda S, Nakamura C.  Influence of Nivolumab for Intercellular Adhesion Force between a T Cell and a Cancer Cell Evaluated by AFM Force Spectroscopy  Sensors (Basel)  2020  20(19):5723  PubMed ID: 33050090   DOI: 10.3390/s20195723
14793  Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y, Yoshimura A, Watanabe S, Kikuchi T, Shiotsu S, Kitazaki T, Nishiyama A, Iwasaku M, Kaneko Y, Uchino J, Uehara H, Horinaka M, Sakai T, Tanaka K, Kozaki R, Yano S, Takayama K.  ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer  Clin Cancer Res  2020  26(9):2244-2256  PubMed ID: 31953310   DOI: 10.1158/1078-0432.CCR-19-2321
14832  Saito S, Kitamura-Muramatsu Y, Komine F, Polat M, Takeshima SN, Takei M, Aida Y.  Absence of bovine leukemia virus proviral DNA in Japanese human blood cell lines and human cancer cell lines  Arch Virol  2020  165(1):207-214  PubMed ID: 31776677   DOI: 10.1007/s00705-019-04474-9
14834  Saito R, Miki Y, Abe T, Miyauchi E, Abe J, Nanamiya R, Inoue C, Sato I, Sasano H.  11β hydroxysteroid dehydrogenase 1: a new marker for predicting response to immune-checkpoint blockade therapy in non-small-cell lung carcinoma  Br J Cancer  2020  123(1):61-71  PubMed ID: 32336752   DOI: 10.1038/s41416-020-0837-3
17870  Yamaguchi T, Hayashi M, Ida L, Yamamoto M, Lu C, Kajino T, Cheng J, Nakatochi M, Isomura H, Yamazaki M, Suzuki M, Fujimoto T, Takahashi T.  ROR1-CAVIN3 interaction required for caveolae-dependent endocytosis and pro-survival signaling in lung adenocarcinoma  Oncogene  2019  38(26):5142-5157  PubMed ID: 30894682   DOI: 10.1038/s41388-019-0785-7
11336  Kosibaty Z, Murata Y, Minami Y, Dai T, Kano J, Matsuoka R, Nakano N, Noguchi M.  Cytoplasmic expression of epithelial cell transforming sequence 2 in lung adenocarcinoma and its implications for malignant progression.  Lab. Invest.  2019    PubMed ID: 30542068   DOI: 10.1038/s41374-018-0142-4
11372  Sun Y, Bandi M, Lofton T, Smith M, Bristow CA, Carugo A, Rogers N, Leonard P, Chang Q, Mullinax R, Han J, Shi X, Seth S, Meyers BA, Miller M, Miao L, Ma X, Feng N, Giuliani V, Geck Do M, Czako B, Palmer WS, Mseeh F, Asara JM, Jiang Y, Morlacchi P, Zhao S, Peoples M, Tieu TN, Warmoes MO, Lorenzi PL, Muller FL, DePinho RA, Draetta GF, Toniatti C, Jones P, Heffernan TP, Marszalek JR.  Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation.  Cell Rep  2019    PubMed ID: 30625329   DOI: 10.1016/j.celrep.2018.12.043
11384  Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S.  AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.  Nat Commun  2019    PubMed ID: 30651547   DOI: 10.1038/s41467-018-08074-0
11421  Masuda T, Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N.  Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts.  J. Cell. Mol. Med.  2019    PubMed ID: 30734495   DOI: 10.1111/jcmm.14205
11453  Kobayashi M, Saito R, Miki Y, Nanamiya R, Inoue C, Abe J, Sato I, Okada Y, Sasano H.  The correlation of p22phox and chemosensitivity in EGFR-TKI resistant lung adenocarcinoma.  Oncotarget  2019    PubMed ID: 30800222   DOI: 10.18632/oncotarget.26637
11461  Imabayashi T, Uchino J, Osoreda H, Tanimura K, Chihara Y, Tamiya N, Kaneko Y, Yamada T, Takayama K.  Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients.  Cancers (Basel)  2019    PubMed ID: 30818860   DOI: 10.3390/cancers11030282
4870  Udagawa H#1, Hasako S#2, Ohashi A, Fujioka R, Hakozaki Y, Shibuya M, Abe N, Komori T, Haruma T, Terasaka M, Fujita R, Hashimoto A, Funabashi K, Yasuda H, Miyadera K, Goto K, Costa DB, Kobayashi S.  TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.  Mol Cancer Res  2019  17(11):2233-2243  PubMed ID: 31467113   DOI: 10.1158/1541-7786.MCR-19-0419
11746  Mizutani K, Guo X, Shioya A, Zhang J, Zheng J, Kurose N, Ishibashi H, Motono N, Uramoto H, Yamada S.  The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma.  Int J Med Sci  2019    PubMed ID: 31588184   DOI: 10.7150/ijms.36071
11808  Sanomachi T, Suzuki S, Togashi K, Seino S, Yoshioka T, Kitanaka C, Okada M, Yamamoto M.  Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer.  Anticancer Res.  2019    PubMed ID: 31519584   DOI: 10.21873/anticanres.13667
11848  Sanomachi T, Suzuki S, Togashi K, Sugai A, Seino S, Okada M, Yoshioka T, Kitanaka C, Yamamoto M.  Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs.  Cancers (Basel)  2019    PubMed ID: 31614999   DOI: 10.3390/cancers11101550
6892  Okita R, Maeda A, Shimizu K, Nojima Y, Saisho S, Nakata M.  Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.  Oncol Rep  2019  42(2):839-848  PubMed ID: 31173242   DOI: 10.3892/or.2019.7185
12553  Chen L, Zhou Y, Tang X, Yang C, Tian Y, Xie R, Chen T, Yang J, Jing M, Chen F, Wang C, Sun H, Huang Y.  EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis  Int J Oncol   2019  54(1):370-380  PubMed ID: 30431083   DOI: 10.3892/ijo.2018.4626
14275  Suzawa K, Offin M, Lu D, Kurzatkowski C, Vojnic M, Smith RS, Sabari JK, Tai H, Mattar M, Khodos I, de Stanchina E, Rudin CM, Kris MG, Arcila ME, Lockwood WW, Drilon A, Ladanyi M, Somwar R.  Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer  Clin Cancer Res  2019  25(4):1248-1260  PubMed ID: 30352902   DOI: 10.1158/1078-0432.CCR-18-1640
14474  Mizuta S, Tagod MSO, Iwasaki M, Nakamura Y, Senju H, Mukae H, Morita CT, Tanaka Y.  Synthesis and Immunomodulatory Activity of Fluorine-Containing Bisphosphonates  ChemMedChem  2019  14(4):462-468  PubMed ID: 30637982   DOI: 10.1002/cmdc.201800764
14810  Namba K, Shien K, Takahashi Y, Torigoe H, Sato H, Yoshioka T, Takeda T, Kurihara E, Ogoshi Y, Yamamoto H, Soh J, Tomida S, Toyooka S.  Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells  Mol Cancer Res  2019  17(2):499-507  PubMed ID: 30463991   DOI: 10.1158/1541-7786.MCR-18-0628
10633  Asaka S, Yoshizawa A, Nakata R, Negishi T, Yamamoto H, Shiina T, Shigeto S, Matsuda K, Kobayashi Y, Honda T.  Utility of bronchial lavage fluids for epithelial growth factor receptor mutation assay in lung cancer patients: Comparison between cell pellets, cell blocks and matching tissue specimens.  Oncol Lett  2018  15:1469-1474  PubMed ID: 29399190   DOI: 10.3892/ol.2017.7464
10679  Yoneda K, Chikaishi Y, Kuwata T, Ohnaga T, Tanaka F.  Capture of mesothelioma cells with 'universal' CTC-chip.  Oncol Lett  2018  15:2635-2640  PubMed ID: 29434985   DOI: 10.3892/ol.2017.7619
10706  Bao H, Bai T, Takata K, Yokobori T, Ohnaga T, Hisada T, Maeno T, Bao P, Yoshida T, Kumakura Y, Honjo H, Sakai M, Sohda M, Fukuchi M, Altan B, Handa T, Ide M, Miyazaki T, Ogata K, Oyama T, Shimizu K, Mogi A, Asao T, Shirabe K, Kuwano H, Kaira K.  High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells is associated with poor clinical response to the immune checkpoint inhibitor nivolumab.  Oncol Lett  2018  15:3061-3067  PubMed ID: 29435038   DOI: 10.3892/ol.2017.7671
10721  Sato H, Sakaguchi M, Yamamoto H, Tomida S, Aoe K, Shien K, Yoshioka T, Namba K, Torigoe H, Soh J, Tsukuda K, Tao H, Okabe K, Miyoshi S, Pass HI, Toyooka S.  Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma.  Oncogenesis  2018  7:11  PubMed ID: 29362358   DOI: 10.1038/s41389-017-0017-3
10768  Kashima Y, Suzuki A, Liu Y, Hosokawa M, Matsunaga H, Shirai M, Arikawa K, Sugano S, Kohno T, Takeyama H, Tsuchihara K, Suzuki Y.  Combinatory use of distinct single-cell RNA-seq analytical platforms reveals the heterogeneous transcriptome response.  Sci Rep  2018  8:3482  PubMed ID: 29472726   DOI: 10.1038/s41598-018-21161-y
10784  Senju H, Kumagai A, Nakamura Y, Yamaguchi H, Nakatomi K, Fukami S, Shiraishi K, Harada Y, Nakamura M, Okamura H, Tanaka Y, Mukae H.  Effect of IL-18 on the Expansion and Phenotype of Human Natural Killer Cells: Application to Cancer Immunotherapy.  Int. J. Biol. Sci.  2018  14:331-340  PubMed ID: 29559850   DOI: 10.7150/ijbs.22809
10785  Torigoe H, Yamamoto H, Sakaguchi M, Youyi C, Namba K, Sato H, Shien K, Soh J, Suzawa K, Tomida S, Tsukuda K, Miyoshi S, Toyooka S.  Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.  Carcinogenesis  2018  39:719-727  PubMed ID: 29546323   DOI: 10.1093/carcin/bgy044
11038  Saito R, Miki Y, Ishida N, Inoue C, Kobayashi M, Hata S, Yamada-Okabe H, Okada Y, Sasano H.  The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting  Int J Mol Sci  2018  19. pii: E609  PubMed ID: 29463039   DOI: 10.3390/ijms19020609
11201  Cao S, Wang Z, Gao X, He W, Cai Y, Chen H, Xu R.  FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC.  J. Exp. Clin. Cancer Res.  2018    PubMed ID: 30189871   DOI: 10.1186/s13046-018-0894-0
11307  Minagawa A, Yoshikawa T, Yasukawa M, Hotta A, Kunitomo M, Iriguchi S, Takiguchi M, Kassai Y, Imai E, Yasui Y, Kawai Y, Zhang R, Uemura Y, Miyoshi H, Nakanishi M, Watanabe A, Hayashi A, Kawana K, Fujii T, Nakatsura T, Kaneko S.  Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy.  Cell Stem Cell  2018    PubMed ID: 30449714   DOI: 10.1016/j.stem.2018.10.005
4141  Suzuki S, Okada M, Takeda H, Kuramoto K, Sanomachi T, Togashi K, Seino S, Yamamoto M, Yoshioka T, Kitanaka C.  Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells.  Oncotarget  2018    PubMed ID: 30220973   DOI: 10.18632/oncotarget.25994
4320  Takeuchi M, Doi T, Obayashi K, Hirai A, Yoneda K, Tanaka F, Iwai Y.  Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.  Immunol. Lett.  2018    PubMed ID: 29366663   DOI: 10.1016/j.imlet.2018.01.007
4321  Shintani T, Higashisaka K, Maeda M, Hamada M, Tsuji R, Kurihara K, Kashiwagi Y, Sato A, Obana M, Yamamoto A, Kawasaki K, Lin Y, Kijima T, Kinehara Y, Miwa Y, Maeda S, Morii E, Kumanogoh A, Tsutsumi Y, Nagatomo I, Fujio Y.  Eukaryotic translation initiation factor 3 subunit C is associated with acquired resistance to erlotinib in non-small cell lung cancer.  Oncotarget  2018    PubMed ID: 30680067   DOI: 10.18632/oncotarget.26494
14901  Enjoji S, Yabe R, Tsuji S, Yoshimura K, Kawasaki H, Sakurai M, Sakai Y, Takenouchi H, Yoshino S, Hazama S, Nagano H, Oshima H, Oshima M, Vitek MP, Matsuura T, Hippo Y, Usui T, Ohama T, Sato K.  Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis  Mol Cancer Res  2018  16(3):554-563  PubMed ID: 29330298   DOI: 10.1158/1541-7786.MCR-17-0393
15838  Hasako S, Terasaka M, Abe N, Uno T, Ohsawa H, Hashimoto A, Fujita R, Tanaka K, Okayama T, Wadhwa R, Miyadera K, Aoyagi Y, Yonekura K, Matsuo K.  TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations  Mol Cancer Ther  2018  17(8):1648-1658  PubMed ID: 29748209   DOI: 10.1158/1535-7163.MCT-17-1206
15842  Zhou P, Chen G, Gao M, Wu J.  Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC  Bioorg Med Chem  2018  26(23-24):6135-6145  PubMed ID: 30442506   DOI: 10.1016/j.bmc.2018.10.018
15843  Saito Y, Moriya S, Kazama H, Hirasawa K, Miyahara K, Kokuba H, Hino H, Kikuchi H, Takano N, Hiramoto M, Tsukahara K, Miyazawa K.  Amino acid starvation culture condition sensitizes EGFR-expressing cancer cell lines to gefitinib-mediated cytotoxicity by inducing atypical necroptosis  Int J Oncol  2018  1165-1177  PubMed ID: 29484439   DOI: 10.3892/ijo.2018.4282
10132  Liu Z, Yanagisawa K, Griesing S, Iwai M, Kano K, Hotta N, Kajino T, Suzuki M, Takahashi T.  TTF-1/NKX2-1 binds to DDB1 and confers replication stress resistance to lung adenocarcinomas.  Oncogene  2017  36:3740-3748  PubMed ID: 28192407   DOI: 10.1038/onc.2016.524
10280  Seike M, Kim CH, Zou F, Noro R, Chiba M, Ishikawa A, Κunugi S, Kubota K, Gemma A.  AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier.  Oncol. Rep.  2017  37:3261-3269  PubMed ID: 28440492   DOI: 10.3892/or.2017.5594
10317  Kurimoto R, Ebata T, Iwasawa S, Ishiwata T, Tada Y, Tatsumi K, Takiguchi Y.  Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma.  Oncol Lett  2017  14:944-950  PubMed ID: 28693256   DOI: 10.3892/ol.2017.6188
10530  Niessen S, Dix MM, Barbas S, Potter ZE, Lu S, Brodsky O, Planken S, Behenna D, Almaden C, Gajiwala KS, Ryan K, Ferre R, Lazear MR, Hayward MM, Kath JC, Cravatt BF.  Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors.  Cell Chem Biol  2017  24:1388-1400.e7  PubMed ID: 28965727   DOI: 10.1016/j.chembiol.2017.08.017
13708  Griesing S, Kajino T, Tai MC, Liu Z, Nakatochi M, Shimada Y, Suzuki M, Takahashi T.  Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells  Cancer Sci   2017  108(7):1394-1404  PubMed ID: 28474808   DOI: 10.1111/cas.13271
14197  Planken S, Behenna DC, Nair SK, Johnson TO, Nagata A, Almaden C, Bailey S, Ballard TE, Bernier L, Cheng H, Cho-Schultz S, Dalvie D, Deal JG, Dinh DM, Edwards MP, Ferre RA, Gajiwala KS, Hemkens M, Kania RS, Kath JC, Matthews J, Murray BW, Niessen S, Orr ST, Pairish M, Sach NW, Shen H, Shi M, Solowiej J, Tran K, Tseng E, Vicini P, Wang Y, Weinrich SL, Zhou R, Zientek M, Liu L, Luo Y, Xin S, Zhang C, Lafontaine J.  Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR  J Med Chem  2017  60(7):3002-3019  PubMed ID: 28287730   DOI: 10.1021/acs.jmedchem.6b01894
14432  Sato T, Shiba-Ishii A, Kim Y, Dai T, Husni RE, Hong J, Kano J, Sakashita S, Iijima T, Noguchi M.  miR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma  Cancer Sci  2017  108(3):536-542  PubMed ID: 28012229   DOI: 10.1111/cas.13148
14449  Asaka S, Yoshizawa A, Matsuda K, Yamaguchi A, Yamamoto H, Shiina T, Nakata R, Ogawa K, Zhang M, Honda T.  A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens  Oncol Rep  2017  37(2):1020-1026  PubMed ID: 27922678   DOI: 10.3892/or.2016.5287
14627  Chikaishi Y, Yoneda K, Ohnaga T, Tanaka F.  EpCAM-independent capture of circulating tumor cells with a 'universal CTC-chip'  Oncol Rep  2017  37(1):77-82  PubMed ID: 27840987   DOI: 10.3892/or.2016.5235
14680  Togo S, Katagiri N, Namba Y, Tulafu M, Nagahama K, Kadoya K, Takamochi K, Oh S, Suzuki K, Sakurai F, Mizuguchi H, Urata Y, Takahashi K.  Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients  Oncotarget  2017  8(21):34884-34895  PubMed ID: 28432274   DOI: 10.18632/oncotarget.16818
14945  Togayachi A, Iwaki J, Kaji H, Matsuzaki H, Kuno A, Hirao Y, Nomura M, Noguchi M, Ikehara Y, Narimatsu H.  Glycobiomarker, Fucosylated Short-Form Secretogranin III Levels Are Increased in Serum of Patients with Small Cell Lung Carcinoma.  J Proteome Res  2017  16:4495-4505  PubMed ID: 28949141   DOI: 10.1021/acs.jproteome.7b00484
15850  Inoue Y, Shiihara J, Miyazawa H, Ohta H, Higo M, Nagai Y, Kobayashi K, Saijo Y, Tsuchida M, Nakayama M, Hagiwara K.  A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung cancer  PLoS One  2017  12(4):e0176525  PubMed ID: 28448556   DOI: 10.1371/journal.pone.0176525
7069  Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, Tanaka H, Chiba K, Ito S, Watatani Y, Kakiuchi N, Suzuki H, Yoshizato T, Yoshida K, Sanada M, Itonaga H, Imaizumi Y, Totoki Y, Munakata W, Nakamura H, Hama N, Shide K, Kubuki Y, Hidaka T, Kameda T, Masuda K, Minato N, Kashiwase K, Izutsu K, Takaori-Kondo A, Miyazaki Y, Takahashi S, Shibata T, Kawamoto H, Akatsuka Y, Shimoda K, Takeuchi K, Seya T, Miyano S, Ogawa S.  Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.  Nature  2016  534:402-6  PubMed ID: 27281199   DOI: 10.1038/nature18294
9511  Yamaguchi T, Lu C, Ida L, Yanagisawa K, Usukura J, Cheng J, Hotta N, Shimada Y, Isomura H, Suzuki M, Fujimoto T, Takahashi T.  ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1.  Nat Commun  2016  7:10060  PubMed ID: 26725982   DOI: 10.1038/ncomms10060
9598  Kurimoto R, Iwasawa S, Ebata T, Ishiwata T, Sekine I, Tada Y, Tatsumi K, Koide S, Iwama A, Takiguchi Y.  Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.  Int. J. Oncol.  2016  48:1825-36  PubMed ID: 26984042   DOI: 10.3892/ijo.2016.3419
9731  Mizutani N, Abe M, Matsuoka S, Kajino K, Wakiya M, Ohtsuji N, Hatano R, Morimoto C, Hino O.  Establishment of anti-mesothelioma monoclonal antibodies.  BMC Res Notes  2016  9:324  PubMed ID: 27342200   DOI: 10.1186/s13104-016-2128-x
9884  Watarai H, Okada M, Kuramoto K, Takeda H, Sakaki H, Suzuki S, Seino S, Oizumi H, Sadahiro M, Kitanaka C.  Impact of H3K27 Demethylase Inhibitor GSKJ4 on NSCLC Cells Alone and in Combination with Metformin.  Anticancer Res.  2016  36:6083-6092  PubMed ID: 27793936   DOI: 10.21873/anticanres.11198
10010  Koh V, Kwan HY, Tan WL, Mah TL, Yong WP.  Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells.  BMC Genomics  2016  17:1029  PubMed ID: 28155658   DOI: 10.1186/s12864-016-3322-x
12883  Ida L, Yamaguchi T, Yanagisawa K, Kajino T, Shimada Y, Suzuki M, Takahashi T.  Receptor tyrosine kinase-like orphan receptor 1, a target of NKX2-1/TTF-1 lineage-survival oncogene, inhibits apoptosis signal-regulating kinase 1-mediated pro-apoptotic signaling in lung adenocarcinoma  Cancer Sci  2016  107(2):155–161  PubMed ID: 26661061   DOI: 10.1111/cas.12858
13967  Lee Y, Choi YR, Kim KY, Shin DH.  The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation  Oncotarget   2016  7(28):43315-43323  PubMed ID: 27270313   DOI: 10.18632/oncotarget.9703
14033  Iyama S, Ono M, Kawai-Nakahara H, Husni RE, Dai T, Shiozawa T, Sakata A, Kohrogi H, Noguchi M.  Drebrin: A new oncofetal biomarker associated with prognosis of lung adenocarcinoma  Lung Cancer  2016  102:74-81  PubMed ID: 27987592   DOI: 10.1016/j.lungcan.2016.10.013
14179  Cheng H, Nair SK, Murray BW, Almaden C, Bailey S, Baxi S, Behenna D, Cho-Schultz S, Dalvie D, Dinh DM, Edwards MP, Feng JL, Ferre RA, Gajiwala KS, Hemkens MD, Jackson-Fisher A, Jalaie M, Johnson TO, Kania RS, Kephart S, Lafontaine J, Lunney B, Liu KK, Liu Z, Matthews J, Nagata A, Niessen S, Ornelas MA, Orr ST, Pairish M, Planken S, Ren S, Richter D, Ryan K, Sach N, Shen H, Smeal T, Solowiej J, Sutton S, Tran K, Tseng E, Vernier W, Walls M, Wang S, Weinrich SL, Xin S, Xu H, Yin MJ, Zientek M, Zhou R, Kath JC.  Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants  J Med Chem  2016  59(5):2005-24  PubMed ID: 26756222   DOI: 10.1021/acs.jmedchem.5b01633
7103  Greig MJ, Niessen S, Weinrich SL, Feng JL, Shi M, Johnson TO.  Effects of Activating Mutations on EGFR Cellular Protein Turnover and Amino Acid Recycling Determined Using SILAC Mass Spectrometry.  Int J Cell Biol  2015  2015:798936  PubMed ID: 26689952   DOI: 10.1155/2015/798936
7346  Yen HY, Liu YC, Chen NY, Tsai CF, Wang YT, Chen YJ, Hsu TL, Yang PC, Wong CH.  Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition.  Proc. Natl. Acad. Sci. U.S.A.  2015  112:6955-60  PubMed ID: 25971727   DOI: 10.1073/pnas.1507329112
7402  Sugita S, Ito K, Yamashiro Y, Moriya S, Che XF, Yokoyama T, Hiramoto M, Miyazawa K.  EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells.  Biochem. Biophys. Res. Commun.  2015  461:28-34  PubMed ID: 25858318   DOI: 10.1016/j.bbrc.2015.03.162
7498  Sakamoto T, Kodani M, Takata M, Chikumi H, Nakamoto M, Nishii-Ito S, Ueda Y, Izumi H, Makino H, Touge H, Takeda K, Yamasaki A, Yanai M, Tanaka N, Igishi T, Shimizu E.  A novel point-of-care system for high-speed real-time polymerase chain reaction testing for epidermal growth factor receptor mutations in bronchial lavage fluids after transbronchial biopsy in patients with non-small cell lung cancer.  Int. J. Oncol.  2015  46:1473-80  PubMed ID: 25651992   DOI: 10.3892/ijo.2015.2875
7523  Elza C. de Bruin, Ming Jiang, Michael Howell, Julian Downward  Genome-Wide siRNA Screen for Anti-Cancer Drug Resistance in Adherent Cell Lines.  Bio-protocol  2015  5:e1474    DOI: 10.21769/BioProtoc.1474
15025  Suzuki A, Matsushima K, Makinoshima H, Sugano S, Kohno T, Tsuchihara K, Suzuki Y.  Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment  Genome Biol  2015  16(1):66  PubMed ID: 25887790   DOI: 10.1186/s13059-015-0636-y
15223  Takahashi A, Ishii G, Ner  Podoplanin-expressing cancer-associated fibroblasts inhibit small cell lung cancer growth  Oncotarget  2015  6(11):9531-41  PubMed ID: 25909164   DOI: 10.18632/oncotarget.3371
15458  Izumi H, Touge H, Igishi T, Makino H, Nishii-Ito S, Takata M, Nakazaki H, Ueda Y, Matsumoto S, Kodani M, Kurai J, Takeda K, Sakamoto T, Yanai M, Tanaka N, Nirodi CS, Shimizu E.  Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies  Int J Oncol  2015  46(3):989-98  PubMed ID: 25573239   DOI: 10.3892/ijo.2015.2815
15825  Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment  Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment  Cancer Sci  2014  105(10):1236-44  PubMed ID: 25154680   DOI: 10.1111/cas.12503
15832  Nozaki K, Kagamu H, Shoji S, Igarashi N, Ohtsubo A, Okajima M, Miura S, Watanabe S, Yoshizawa H, Narita I.  DDX3X induces primary EGFR-TKI resistance based on intratumor heterogeneity in lung cancer cells harboring EGFR-activating mutations  PLoS One  2014  9(10):e111019  PubMed ID: 25343452   DOI: 10.1371/journal.pone.0111019
16301  Xue R, Han N, Sakurai H, Saiki I, Ye C, Yin J.  Cytotoxic cardiac glycosides from the roots of Streptocaulon juventas  Planta Med  2013  79(2):157-62  PubMed ID: 23225367   DOI: 10.1055/s-0032-1328021
15834  Takata M, Chikumi H, Miyake N, Adachi K, Kanamori Y, Yamasaki A, Igishi T, Burioka N, Nanba E, Shimizu E.  Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity  Cancer Biol Ther  2012  13(6):369-78.  PubMed ID: 22313637   DOI: 10.4161/cbt.19238
15715  Menju T, Hashimoto S, Hashimoto A, Otsuka Y, Handa H, Ogawa E, Toda Y, Wada H, Date H, Sabe H.  Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma  PLoS One  2011  6(9):e25301  PubMed ID: 21966491   DOI: 10.1371/journal.pone.0025301
15844  Hotta K, Tabata M, Kiura K, Kozuki T, Hisamoto A, Katayama H, Takigawa N, Fujimoto N, Fujiwara K, Ueoka H, Tanimoto M.  Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation  Oncol Rep  2007  17(2):313-7  PubMed ID: 17203166  

Back Back Return Top Page